Department of Infectious Diseases, Institute of Biomedicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Centre for Antibiotic Resistance Research (CARe) at University of Gothenburg, Gothenburg, Sweden.
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01817-18. Print 2019 Jan.
While carbapenem resistance in Gram-negative bacteria is mainly due to the production of efficient carbapenemases, β-lactamases with a narrower spectrum may also contribute to resistance when combined with additional mechanisms. OXA-10-type class D β-lactamases, previously shown to be weak carbapenemases, could represent such a case. In this study, two novel OXA-10 variants were identified as the sole carbapenem-hydrolyzing enzymes in meropenem-resistant enterobacteria isolated from hospital wastewater and found by next-generation sequencing to express additional β-lactam resistance mechanisms. The new variants, OXA-655 and OXA-656, were carried by two related IncQ1 broad-host-range plasmids. Compared to the sequence of OXA-10, they both harbored a Thr26Met substitution, with OXA-655 also bearing a leucine instead of a valine in position 117 of the SAV catalytic motif. Susceptibility profiling of laboratory strains replicating the natural plasmids and of recombinant clones expressing OXA-10 and the novel variants in an isogenic background indicated that OXA-655 is a more efficient carbapenemase. The carbapenemase activity of OXA-655 is due to the Val117Leu substitution, as shown by steady-state kinetic experiments, where the of meropenem hydrolysis was increased 4-fold. In contrast, OXA-655 had no activity toward oxyimino-β-lactams, while its catalytic efficiency against oxacillin was significantly reduced. Moreover, the Val117Leu variant was more efficient against temocillin and cefoxitin. Molecular dynamics indicated that Val117Leu affects the position 117-Leu155 interaction, leading to structural shifts in the active site that may alter carbapenem alignment. The evolutionary potential of OXA-10 enzymes toward carbapenem hydrolysis combined with their spread by promiscuous plasmids indicates that they may pose a future clinical threat.
虽然革兰氏阴性菌的碳青霉烯耐药性主要归因于高效碳青霉烯酶的产生,但当与其他机制结合时,具有较窄谱的β-内酰胺酶也可能导致耐药性。先前被证明为弱碳青霉烯酶的 OXA-10 型类 Dβ-内酰胺酶可能就是这种情况。在这项研究中,两种新型 OXA-10 变体被鉴定为从医院废水分离的耐美罗培南肠杆菌中唯一的碳青霉烯水解酶,并通过下一代测序发现其表达了额外的β-内酰胺耐药机制。这两种新变体,OXA-655 和 OXA-656,均由两个相关的 IncQ1 广谱质粒携带。与 OXA-10 的序列相比,它们都携带 Thr26Met 取代,而 OXA-655 在 SAV 催化基序的位置 117 处还带有亮氨酸而不是缬氨酸。对复制天然质粒的实验室菌株和在同种背景下表达 OXA-10 和新型变体的重组克隆的药敏谱分析表明,OXA-655 是一种更有效的碳青霉烯酶。通过稳态动力学实验表明,OXA-655 的碳青霉烯酶活性归因于 Val117Leu 取代,美罗培南水解的 kcat 增加了 4 倍。相比之下,OXA-655 对氧亚氨基-β-内酰胺没有活性,但其对苯唑西林的催化效率显著降低。此外,Val117Leu 变体对替莫西林和头孢西丁的效率更高。分子动力学表明,Val117Leu 影响位置 117-Leu155 的相互作用,导致活性位点的结构移位,从而可能改变碳青霉烯的排列。OXA-10 酶向碳青霉烯水解的进化潜力与它们通过混杂质粒的传播相结合,表明它们可能对未来的临床构成威胁。